Endocyte -2.4% AH after pricing 4.5M-share offering at $21

Endocyte's (ECYT) offering price is 9% below today's closing price of $23.07. The drug developer stands to reap gross proceeds of $94.5M, assuming the 675K-share overallotment option isn't exercised.

Shares had already fallen 15% over the last two trading days, following Endocyte's original offering announcement.

Comments (2)
  • ECapo
    , contributor
    Comments (735) | Send Message
    Amazing, so high up on such news and here we go down as several analyst upgrades to 40.00? I guess we need the analyst to downgrade?
    27 Mar 2014, 07:04 PM Reply Like
  • Stealthe
    , contributor
    Comments (88) | Send Message
    Seriously... Out with one drug and that give you permission to print out shares.
    27 Mar 2014, 08:51 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs